

Nivolumab
Essential medicine status
General description

INN
Nivolumab
ATC codes

[L01FF01](#)

Medicine type
Biological agent
EML status history

First added in 2019 ([TRS 1021](#)) for [Melanoma of skin](#)

Application rejected in 2019 ([TRS 1021](#)) for [Other specified malignant neoplasms of bronchus or lung](#)

Added in 2025 ([TRS 1064](#)) for [Melanoma of skin](#)

Application rejected in 2025 ([TRS 1064](#)) for [Renal cell carcinoma of kidney, except renal pelvis](#)

Application rejected in 2025 ([TRS 1064](#)) for [Squamous cell carcinoma of oesophagus](#)

Application rejected in 2025 ([TRS 1064](#)) for [Adenocarcinoma of oesophagogastric junction](#)

Application rejected in 2025 ([TRS 1064](#)) for [Adenocarcinoma of stomach](#)

Therapeutic equivalent for

[pembrolizumab](#) for [Melanoma of skin](#)

Wikipedia

[Nivolumab](#)

DrugBank

[Nivolumab](#)

Recommendations

Section

Immunomodulators

- Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

Indications

[Melanoma of skin](#) [Other specified malignant neoplasms of bronchus or lung](#) [Renal cell carcinoma of kidney, except renal pelvis](#) [Squamous cell carcinoma of oesophagus](#) [Adenocarcinoma of oesophagogastric junction](#) [Adenocarcinoma of stomach](#)